Navigation Links
Life Technologies Announces Fourth Quarter and Fiscal 2012 Results
Date:2/4/2013

set impairments, and in process research and development expenses, incurred as a result of business combinations as well as the impact from the divestiture and discontinuance of product lines.  The Company also excludes noncash interest expense associated with convertible debt bifurcation and noncash charges associated with non-controlling interests. In addition, the Company excludes one-time costs including the early repayment of debt and the associated impacts, and the impact of certain settlements in order to provide a supplemental comparison of the results of operations.  LIFE TECHNOLOGIES CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONSFor the yearFor the year(in thousands, except per share data)ended December 31, 2012ended December 31, 2011(unaudited)Revenues$
3,798,510$
3,775,672Cost of revenues

1,372,2771,356,967Purchased intangibles amortization

291,756308,728Gross profit

2,134,4772,109,977Gross margin56.2%55.9%Operating expenses:Selling, general and administrative

1,054,6161,008,973Research and development

341,892377,924Business consolidation costs

72,73275,324Total operating expenses

1,469,2401,462,221Operating income

665,237647,756Operating margin

17.5%17.2%Interest income

2,4013,932Interest expense

(123,915)(162,073)Other expense, net

(11,898)(10,913)Total other expense, net

(133,412)(169,054)Income from operations before provision for income taxes

531,825478,702Income tax provision

(101,376)(100,868)Net income

430,449377,834Net loss attributable to non-controlling interests

406658Net income attributable to controlling interest$
430,855$
378,492Effective tax rate 

19.1%21.1%Add back interest expense for subordinated

SOURCE Life Technologies Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Palatin Technologies, Inc. to Report Fiscal Year 2012 First Quarter Results; Teleconference and Webcast to be held on November 15, 2011
2. UV Flu Technologies Expands Its International Footprint
3. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
4. OrthoAccel® Technologies, Inc. Announces Definitive Distribution Agreement in Italy
5. Hologic to Showcase 3D Mammography (Breast Tomosynthesis) and Other Advanced Womens Imaging Technologies at RSNA 2011, the Largest Radiology Show in the World
6. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
7. Senesco Technologies, Inc. to Webcast, Live, at RetailInvestorConferences.com on December 1st
8. Animal Biotechnology - Technologies, Markets and Companies
9. Gene Therapy - Technologies, Markets and Companies
10. Biomarkers - Technologies, Markets and Companies
11. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Research and Markets  has announced the addition of the ... Report" report to their offering. This ... (SOFCs) in US$ Thousands. The report provides separate comprehensive analytics ... Europe , Asia-Pacific , and Rest ... period 2012 through 2020. Market data and analytics are derived ...
(Date:8/19/2014)... 19, 2014 In November 2012, the European ... Evaluation Report (PBRER) in a new PSUR – responding to ... benefit-risk profile of a drug. Adopted in many regions, the ... Present a comprehensive and critical analysis of new or ... Highlight any new evidence of the potential benefits of ...
(Date:8/18/2014)... A new therapy developed by researchers at the ... Medicine and Columbia University Medical Center (CUMC) may ... disease treatment. , The researchers demonstrated in ... could selectively inhibit blood vessel re-narrowing and simultaneously ... a balloon catheter to open narrowed or blocked ...
(Date:8/18/2014)... Global HIV Infection Drug Market and Pipeline Insight ... of HIV infection and the number of deaths due to ... rate across the globe. It has been estimated that the ... in 2013, with the rates for children being even much ... infection rates has been the improved access to antiretroviral drugs ...
Breaking Biology Technology:Global Solid Oxide Fuel Cells (SOFCs) - Strategic Business Report 2014 2Top Five Best Practices for Developing Your Periodic Benefit Risk Evaluation Report (PBRER), New Webinar Hosted by Xtalks 2Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Global HIV Infection Drug Market Overview 2Global HIV Infection Drug Market Overview 3Global HIV Infection Drug Market Overview 4
... Hospitals in Western Pennsylvania Earn Designation, PITTSBURGH, ... named Allegheny General Hospital, UPMC Presbyterian Shadyside and ... Rare Cancers., Complex and rare cancers comprise ... making it difficult for patients to locate or,research ...
... has announced,development of a chemically synthesized vaccine specific ... patented Replikins(TM) technology.,When the vaccine was administered orally ... Taura virus. The specificity of the protective,effect was ... active,regions in the vaccine, and as a result ...
... Prescribing of Copaxone over an Interferon-Beta Therapy, According to a ... ... Resources, WALTHAM, Mass., March 11 Decision Resources, one ... issues, finds that Teva Pharmaceutical,s Copaxone has the,greatest patient share among ...
Cached Biology Technology:Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 2Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 3Replikins Oral Vaccine Synthesized in 7 Days Protects 91% of Shrimp Against a Lethal Virus 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 2Teva Pharmaceutical's Altered Peptide Ligand Copaxone Boasts the Greatest Patient Share Among First- and Second-Line Therapies for the Treatment of Multiple Sclerosis 3
(Date:8/19/2014)... and tuberculosis live side-by-side. Worldwide there are approximately ... nearly all of them occurring where tuberculosis is ... or BCG, provides only partial protection against both ... is needed to combat both diseases. UCLA-led research ... diseases., In a study published in the September ...
(Date:8/19/2014)... CAMBRIDGE, MA -- MIT chemical engineers have devised a ... that are released slowly over a few weeks. When ... induces the body to rapidly form new bone that ... This type of coated scaffold could offer a dramatic ... which involves transplanting bone from another part of the ...
(Date:8/19/2014)... with neonatal abstinence syndrome (NAS) secondary to in-utero ... through withdrawal than others, but the underlying reasons ... (when genes are turned on or off) changes ... at Boston University School of Medicine (BUSM) and ... its kind study to identify some of these ...
Breaking Biology News(10 mins):New vaccine shows promise as stronger weapon against both tuberculosis and leprosy 2Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2
... may help to identify which depressed patients will ... signal, detectable by noninvasive imaging, also holds clues ... for drug development, say National Institutes of Health ... of several such markers, including factors detectable in ...
... pollution and heavy fishingare adding insult to injury in ... by the Wildlife Conservation Society and the University of ... found that pollution and overfishing on reef systems have ... wormsthat further degrade corals, a discovery that underlines the ...
... University of Oklahoma research team has been awarded a five-year, ... that can lead to a greater understanding of human diseases ... infections. The goal of the NIH grant is to ... research in Oklahoma. "This is the first NIH ...
Cached Biology News:Brain signal IDs responders to fast-acting antidepressant 2Brain signal IDs responders to fast-acting antidepressant 3Brain signal IDs responders to fast-acting antidepressant 4Brain signal IDs responders to fast-acting antidepressant 5Brain signal IDs responders to fast-acting antidepressant 6Microbes, sponges, and worms add to coral reef woes 2Microbes, sponges, and worms add to coral reef woes 3OU research group awarded $9.7 million NIH CoBRE grant in structural biology 2
Designed for use with all 96-well SPRI reagent kits. Used with round bottom 96-well microplates, and 96-well thermal cycling plates....
... Polystyrene covers can be ... Ridged covers for stacking ... Non-ridged covers for use with ... covers, ridged and non-ridged, are ...
... can be used with all ... for stacking of covered plates ... use with automated systems ... non-ridged, are available for use ...
... made from an inert polymer with a unique ... 384 split septum caps for use with 384-well ... PCR when used in conjunction with screw or ... standard pipetting equipment 384 septum caps may ...
Biology Products: